Akademik Veri Yönetim Sistemi
Turk Onkoloji Dergisi, cilt.41, sa.1, ss.28-35, 2026 (ESCI, Scopus, TRDizin)
OBJECTIVE Nasopharyngeal cancer (NPC) is highly treatment-sensitive, yet distant metastasis remains a challenge. Data on adjuvan therapy needs in non-metastatic (NM) cases from non-endemic regions (NERs) are limited. This retrospective cohort analysis aimed to evaluate the prognostic impact of PD-L1 and Tumor Proportion Score (TPS) in NM NPC patients from a NER. METHODS We retrospectively analyzed PD-L1 expression in tumor samples of patients with locoregionally confined NPC. TPS, derived from PD-L1 expression, was correlated with clinical outcomes. Data were analyzed using SPSS 26 with t-tests and chi-square tests for group comparisons, Kaplan–Meier, and Cox regression analyses for survival assessment. RESULTS The study included 60 patients with a mean follow-up of 114.5 months. The TPS expression stratified into two groups as <43 (n=24), and ≥43 (n=36). Statistically significant differences were observed in treatment response across the TPS subgroups (p<0.05). TPS≥43 was associated with significantly longer overall survival compared to lower TPS expression (p<0.05). CONCLUSION TPS expression ≥43 was significantly associated with longer survival and better treatment response in NM NPC. These findings support the use of TPS as a prognostic biomarker, which could guide clinical adjuvant treatment studies that improve survival rates and treatment effectiveness. These results underscore the significance of ongoing research and the development of personalized treatment plans for NM NPC patients.